Sinovac Biotech (TSE:SVA) Receives Buy Rating from Echelon Wealth Partners

Echelon Wealth Partners restated their buy rating on shares of Sinovac Biotech (TSE:SVAGet Rating) in a research note published on Tuesday morning, TipRanks reports. The brokerage currently has a C$3.75 price objective on the stock.

About Sinovac Biotech (Get Rating)

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide (‘PPV’), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps.

See Also

Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.